ThinkEquity upgraded shares of Radiopharm Theranostics Limited – American Depositary Shares (NASDAQ:RADX – Free Report) to a strong-buy rating in a research report released on Monday morning,Zacks.com reports.
Separately, Maxim Group assumed coverage on shares of Radiopharm Theranostics Limited – American Depositary Shares in a report on Thursday, May 1st. They set a “buy” rating and a $12.00 price target for the company.
View Our Latest Stock Analysis on RADX
Radiopharm Theranostics Limited – American Depositary Shares Stock Performance
About Radiopharm Theranostics Limited – American Depositary Shares
Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.
Featured Articles
- Five stocks we like better than Radiopharm Theranostics Limited – American Depositary Shares
- How to Choose Top Rated Stocks
- Is Bally’s Turnaround a Safe Bet Amid Mixed Investor Sentiment?
- Pros And Cons Of Monthly Dividend Stocks
- Steepening Yield Curve? These 3 Bank Stocks Are Poised to Profit
- Dividend Payout Ratio Calculator
- Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025
Receive News & Ratings for Radiopharm Theranostics Limited - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radiopharm Theranostics Limited - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
